With the support of Small Business Innovation and Research (SBIR) grants awarded by the National Institutes of Health (NIH), Axion PNI is developing products for two neuroscience markets. The first product is a medical diagnostic tool intended to replace conventional nerve conduction studies (NCS). Conventional NCS uses two macro-electrodes to measure the degeneration of motor and sensory nerves. This painful, trial-and-error process does not lend itself to ease-of-use, accuracy, or productivity improvements.
In contrast, Axion PNI’s proprietary technology provides a 25-fold increase in resolution over existing surface electrode NCS systems, opening the door to reliably monitoring difficult-to-find nerves or measuring multiple nerves simultaneously. This microelectrode-based technology removes the trial-and-error nature of today’s nerve conduction tests, while generating new clinical applications for neuropathic monitoring. Ultimately, Axion believes that our microneedle electrode patch approach will generate significantly more accurate, productive, and comfortable tests.
In addition, Axion PNI is developing implantable microelectrodes to stimulate brain activity. For example, deep brain stimulation (DBS) is used to treat Parkinson’s disease and companies develop, manufacture and sell implantable devices to reduce or manage Parkinson’s symptoms. The devices currently on the market apply non-stop stimulation using rigid materials to targeted tissues in the brain. In contrast, Axion can once again utilize our patented ASIC and microfabrication methods to create a unique product. Combining our conformable microelectrode arrays with our artifact-eliminating chip enables a more precise and regulated stimulation, and has the potential to significantly improve current products on the market.